Related Experiment Video
Updated: May 10, 2025
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
Single-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting
Ren-Peng Li1,2,3, Guo-Zhi Wu1,2,3, Xi-Dong Fang1,2,3
1The First Clinical Medical College, Lanzhou University, Lanzhou, People's Republic of China.
Objective:
This study aims to identify specific molecular targets sensitive to AZD6738 through the integration of network pharmacology and transcriptomic methods, and to assess their potential role in the treatment of hepatocellular carcinoma (HCC). Additionally, we explore the specific effects of AZD6738 on the tumor microenvironment and its ability to regulate immune responses.
Methods:
We employed a combination of network pharmacology and transcriptomic analysis to identify specific molecules associated with HCC, including EZH2, CCNB1, PRKDC, CTSL, PSEN1, SLC6A3, and FKBP1A. Using these molecules and clinical features, we constructed a robust prognostic model for HCC. We further used single-cell transcriptomic technology to screen for core targets and performed spatial transcriptomic analysis to determine their spatial distribution. To validate the efficacy of AZD6738 in vivo, we established a subcutaneous tumor model, with the experimental group receiving oral administration of AZD6738 (75 mg/kg). Finally, we assessed the changes in the immune cell expression profile in tumor tissues post-AZD6738 treatment using flow cytometry.
Results:
Our study indicates that the high expression of genes such as EZH2, CCNB1, PRKDC, and PSEN1 is associated with poor prognosis in HCC patients. Molecular docking and RT-PCR validation demonstrated that AZD6738 exhibits high affinity for these targets and significantly reduces the mRNA levels of EZH2, PRKDC, and CCNB1 in HCC cell lines, with EZH2 showing the most pronounced decrease. Animal experiments revealed that AZD6738 can enhance the immune microenvironment in liver cancer; specifically, AZD6738 not only promotes the proliferation of CD8+ T cells but also enhances their differentiation into effector memory T cells, indicating that the drug can potentiate anti-tumor immune responses.
Conclusion:
This study reveals that AZD6738 demonstrates significant therapeutic efficacy by targeting the key molecule EZH2, thereby modulating the tumor microenvironment and enhancing anti-tumor immunity.
Insights
AZD6738 shows promise in treating hepatocellular carcinoma (HCC) by targeting EZH2, enhancing anti-tumor immunity, and improving the tumor microenvironment. This drug effectively reduces key gene expression and boosts CD8+ T cell activity for better cancer treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge with limited effective targeted therapies.
- Identifying novel molecular targets and therapeutic strategies is crucial for improving HCC patient outcomes.
Purpose of the Study:
- To identify molecular targets for AZD6738 in hepatocellular carcinoma (HCC) using network pharmacology and transcriptomic analysis.
- To evaluate the therapeutic potential of AZD6738 in modulating the HCC tumor microenvironment and immune responses.
Main Methods:
- Integrated network pharmacology and transcriptomic analysis to identify key HCC-associated molecules (e.g., EZH2, CCNB1).
- Construction of a prognostic model for HCC using identified molecules and clinical data.
- In vivo validation of AZD6738 efficacy in a subcutaneous HCC tumor model and assessment of immune cell profiles via flow cytometry.
Main Results:
- High expression of EZH2, CCNB1, PRKDC, and PSEN1 correlates with poor HCC prognosis.
- AZD6738 demonstrated high affinity for identified targets, significantly reducing EZH2, PRKDC, and CCNB1 mRNA levels in HCC cell lines.
- AZD6738 treatment enhanced the anti-tumor immune microenvironment by promoting CD8+ T cell proliferation and differentiation.
Conclusions:
- AZD6738 exhibits significant therapeutic efficacy in HCC by targeting EZH2.
- AZD6738 modulates the tumor microenvironment and potentiates anti-tumor immunity, offering a promising therapeutic strategy for HCC.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
